Provided by Tiger Trade Technology Pte. Ltd.

SpringWorks Therapeutics, Inc.

46.99
0.0000
Volume:- -
Turnover:235.41M
Market Cap:3.54B
PE:-13.77
High:46.99
Open:46.99
Low:46.99
Close:46.99
52wk High:62.00
52wk Low:28.21
Shares:75.35M
Float Shares:74.19M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4125
EPS(LYR):-3.4820
ROE:-51.57%
ROA:-28.47%
PB:8.48
PE(LYR):-13.50

Loading ...

Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal

Reuters
·
Nov 20

Merck KGaA third-quarter net sales rise 1.0% to €5.3 billion

Reuters
·
Nov 13

Germany's Merck eyes life science deals, but muted 2026 outlook knocks shares

Reuters
·
Oct 16

Springworks Therapeutics Gets European Commission Approval for Ogsiveo in Desmoid Tumors

MT Newswires Live
·
Aug 18

European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU

Reuters
·
Aug 18

MEDIA-Merck KGaA plans $4 billion bond sale to fund SpringWorks Therapeutics acquisition - Bloomberg News

Reuters
·
Aug 12

Merck KGaA raises forex-adj profit guidance on drugs, lab gear

Reuters
·
Aug 07

SpringWorks Says EC Conditionally Approved EZMEKLY In Adults, Children

Reuters
·
Jul 19

Merck European Commission Grants Conditional Approval Of Ezmekly

Reuters
·
Jul 18

SpringWorks Therapeutics Inc. Finalizes Merger, Offering $47 Per Share to Stockholders

Reuters
·
Jul 01

BRIEF-Springworks Therapeutics Inc - Merck KGaA, Darmstadt, Germany Completes Acquisition Of Springworks Therapeutics To Accelerate Sustainable Growth Of Its Healthcare Business

Reuters
·
Jul 01

SpringWorks Therapeutics Inc. Conducted Special Stockholder Meeting

Reuters
·
Jun 27

BRIEF-Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3

Reuters
·
Jun 20

SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025

Reuters
·
Jun 20

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
·
Jun 20

SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025

Reuters
·
Jun 16

SpringWorks Therapeutics Inc. Announces Date for Special Stockholders Meeting

Reuters
·
May 28